-
Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma
-
Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
-
Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy
-
Ultimovacs ASA: First quarter 2022 result presentation
-
Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting
-
Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation
-
Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations
-
Ultimovacs ASA – Share Option Program
